Publication:
Nine-month course of SARS-CoV-2 antibodies in individuals with COVID-19 infection

dc.contributor.authorTürkkan, Alpaslan
dc.contributor.authorSağlık, İmran
dc.contributor.authorTuran, Cansu
dc.contributor.authorŞahin, Ahmet
dc.contributor.authorAkalın, Halis
dc.contributor.authorEner, Beyza
dc.contributor.authorKara, Ateş
dc.contributor.authorÇelebi, Solmaz
dc.contributor.authorŞahin, Emre
dc.contributor.authorHacımustafaoğlu, Mustafa
dc.contributor.buuauthorTÜRKKAN, ALPASLAN
dc.contributor.buuauthorSAĞLIK, İMRAN
dc.contributor.buuauthorTURAN, CANSU
dc.contributor.buuauthorAKALIN, EMİN HALİS
dc.contributor.buuauthorENER, BEYZA
dc.contributor.buuauthorÇELEBİ, SOLMAZ
dc.contributor.buuauthorŞAHİN, EMRE
dc.contributor.buuauthorHACIMUSTAFAOĞLU, MUSTAFA KEMAL
dc.contributor.departmentBursa Uludağ Üniversitesi/Tıp Fakültesi/Halk Sağlığı Anabilim Dalı.
dc.contributor.departmentBursa Uludağ Üniversite/Tıp Fakültesi/Tıbbi Mikrobiyoloji Anabilim Dalı.
dc.contributor.departmentBursa Uludağ Üniversite/Tıp Fakültesi/Çocuk Enfeksiyon Hastalıkları Anabilim Dalı.
dc.contributor.departmentBursa Uludağ Üniversitesi/Tıp Fakültesi/Enfeksiyon Hastalıkları ve Klinik Anabilim Dalı.
dc.contributor.orcid0000-0003-0864-4989
dc.contributor.orcid0000-0003-3146-6391
dc.contributor.orcid0000-0002-4415-076X
dc.contributor.orcid0000-0001-7530-1279
dc.contributor.orcid0000-0002-1654-3232
dc.contributor.orcid0000-0003-4646-660X
dc.contributor.researcheridGFL-2282-2022
dc.contributor.researcheridGCM-3391-2022
dc.contributor.researcheridIVB-4013-2023
dc.contributor.researcheridAAU-8952-2020
dc.contributor.researcheridCNK-0895-2022
dc.contributor.researcheridENK-4130-2022
dc.contributor.researcheridJFP-8395-2023
dc.contributor.researcheridCTG-5805-2022
dc.date.accessioned2024-11-12T12:12:39Z
dc.date.available2024-11-12T12:12:39Z
dc.date.issued2022-01-20
dc.description.abstractBackground The continual course of the pandemic points to the importance of studies on the rate and durability of protective immunity after infection or vaccination. Aims In this study, we aimed to monitor anti-nucleocapsid (N) and anti-spike (S) antibodies against SARS-CoV-2 nearly 9 months duration after infection. Methods Anti-nucleocapsid (N) (at 11-15-20-29-38 weeks) and anti-spike antibodies (at 11 and 38 weeks) against SARS-CoV-2 were monitored during 38 weeks after the initial symptoms of COVID-19. Results Of 37 cases between 18 and 57 years old, 54% were women. The findings showed that anti-N antibodies decreased significantly after the 15th week (between 15 and 20 weeks, p = 0.016; 20-29 weeks, p = 0.0009; and 29-38 weeks, p = 0.049). At the 38th week, mean antibody levels decreased 35% compared to the 11th week, and 8% of the cases turned negative results. Anti-N antibody average level was 56.48 on the 11th week (the cut-off index threshold >= 1). It was estimated statistically that it would decrease to an average of 20.48 in weeks 53-62. In females, average antibody levels of all measurements were lower than males (p > 0.05). Anti-S antibody levels 14% increased at 38th week compared to 11th week (quantitative positivity threshold >= 0.8 U/ml), and no cases were negative at 38th week. Conclusions Patients had >= 90% positivity after at least 9 months of symptoms, both anti-N and anti-S antibodies. In all samples, both anti-N and anti-S antibody levels were lower in females. The findings suggest that the quantitative values of anti-S antibodies remained high for at least 9 months and could provide protection.
dc.identifier.doi10.1007/s11845-021-02716-x
dc.identifier.endpage2811
dc.identifier.issn0021-1265
dc.identifier.issue6
dc.identifier.startpage2803
dc.identifier.urihttps://doi.org/10.1007/s11845-021-02716-x
dc.identifier.urihttps://link.springer.com/article/10.1007/s11845-021-02716-x
dc.identifier.urihttps://hdl.handle.net/11452/47778
dc.identifier.volume191
dc.identifier.wos000745771100001
dc.indexed.wosWOS.SCI
dc.language.isoen
dc.publisherSpringer London Ltd
dc.relation.journalIrish Journal of Medical Science
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectCoronavirus
dc.subjectResponses
dc.subjectKinetics
dc.subjectAntibody
dc.subjectCovid-19
dc.subjectPersistence
dc.subjectSars-cov-2
dc.subjectGeneral & internal medicine
dc.titleNine-month course of SARS-CoV-2 antibodies in individuals with COVID-19 infection
dc.typeArticle
dspace.entity.typePublication
relation.isAuthorOfPublicationdece2ce8-2e40-44fd-9cc1-b52d5f2cb79a
relation.isAuthorOfPublicationaab7d5dd-72a4-4f3a-a677-1fdf3e13cadc
relation.isAuthorOfPublication92778d28-f35c-48cf-ae86-8046442203bb
relation.isAuthorOfPublication4fb46529-3295-4383-97b1-7c494ff32c24
relation.isAuthorOfPublication2b082cc1-092b-441d-bafb-e08676bd66bb
relation.isAuthorOfPublication28076e30-7802-4de2-ae05-028643d56968
relation.isAuthorOfPublicationc100ffd6-14d9-4678-9af4-22b9268061eb
relation.isAuthorOfPublication0f1ad7e3-4cce-40b2-bbb3-7200fae5f769
relation.isAuthorOfPublication.latestForDiscoverydece2ce8-2e40-44fd-9cc1-b52d5f2cb79a

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Turkkan_vd_2022.pdf
Size:
727.81 KB
Format:
Adobe Portable Document Format

Collections